Clinical trial

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

NCT02228265

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2013-03-12

PhaseN/A

Study timeline

Study start (actual)2013-03-12Date precision: day

Registry last updated2020-09-28

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Castration Levels of Testosteroneunresolved

Castration-Resistant Prostate Carcinomaunresolved

Prostate Adenocarcinomaunresolved

PSA Progressionunresolved

Recurrent Prostate Carcinomaunresolved

Stage IV Prostate Cancerunresolved

Interventions

Cytology Specimen Collection ProcedureOTHER

EnzalutamideDRUG · verified · RxNorm: enzalutamide

Laboratory Biomarker AnalysisOTHER

Sponsors & collaborators

OHSU Knight Cancer Institutelead sponsor

United States Department of Defensecollaborator

Oregon Health and Science Universitycollaborator

Mapped research locations

Los AngelesCalifornia, United States1 San FranciscoCalifornia, United States1 PortlandOregon, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02228265 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.